Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Steve Fancy who wrote (5523)	10/19/1998 2:37:00 PM
From: Steve Fancy	Read Replies (1) \| Respond to of 6136

Weekly scrip data for week ending 10/9... New 4088 -1.4% Refills 7510 -3.5% Total 11,598 -2.8% Monthly scrip data for September... New 19,043 +5.2% unadj Refills 33,357 +4.8% unadj Total 52400 +5% unadj Comments suggest holding at 32% market share and they remain ahead of competitors in total PI sales. sf

To: Steve Fancy who wrote (5523)	10/19/1998 2:39:00 PM
From: Steve Fancy	Read Replies (1) \| Respond to of 6136

The comments last week came from Ms Wong. She apparently stated that a competitor is feeling AGPH may miss their numbers...not sure who the competitor was. My broker had filled in the blank with RS, but admitted today that he didn't know. Elise apparently went on to say that she is confident they will hit her estimate of .21. sf

To: Steve Fancy who wrote (5523)	10/19/1998 4:55:00 PM
From: Bradpalm1	Read Replies (1) \| Respond to of 6136

I've heard very positive rumors about AGPH's MMP inhibitor AG3340 in early Phase II/III trials for metastatic non-small lung cancer. With the recent elite status conferred upon anything 'anti-angiogenesis', perhaps word is filtering down to the street. These studies bear close monitoring. Bradpalm1

To: Steve Fancy who wrote (5523)	10/19/1998 5:07:00 PM
From: Steve Fancy	Respond to of 6136

Another version of the IMNR news... Immune Response, Agouron To Work Together On HIV Treatment Dow Jones Online News, Monday, October 19, 1998 at 16:57 CARLSBAD, Calif. -(Dow Jones)- Immune Response Corp. said Monday Agouron Pharmaceuticals Inc. agreed to collaborate on the development and sale of Remune, an experimental HIV treatment that aims to boost patients' immune systems to fight the virus. Immune Response, a biopharmaceutical company, said it may receive as much as $77 million over the next two years, and the two companies will share all Remune profits on a 50/50 basis. Agouron is known for making Viracept, a protease inhibitor taken as part of a so-called "drug cocktail." The drug combinations have been cited with revolutionizing AIDS treatment because they can drive HIV in the bloodstream down to nearly undetectable levels. Remune is an experimental vaccine. It contains only proteins inside the core of HIV, and not its outer envelope. Scientists think that with virus levels reduced significantly by treatment with the combination drug therapy, the immune system can create so-called helper cells once it sees the HIV proteins contained in Remune. Immune Response (IMNR) received an initial $3 million research and development payment and $2 million for the purchase of 126,758 unregistered common shares. The shares were purchased at a premium, the company said. Immune Response said Agouron (AGPH) is expected to make a series of quarterly research and development payments and to purchase unregistered common shares. Immune Response will manufacture Remune's commercial supply. Agouron will have exclusive rights to market the treatment in North America, Europe and other countries, after receipt of regulatory approvals. Copyright (c) 1998 Dow Jones & Company, Inc. All Rights Reserved.